Summary

Other Scenarios:

Buyer: MedImmune, Inc. (MEDI) Last Price: 57.94 Market Cap.: 13.84B
Target: Medicis Pharmaceutical Corporation (MRX) Last Price: 31.30 Market Cap.: 1.75B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 884
Biopharmaceuticals 342
Medical Devices   246

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 36)
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • MEDI-545 (Anti-Interferon Alpha Monoclonal Antibody)
  • MDX-1103 (Human Antibodies)
  • MEDI-546 (Anti-Type 1 Interferon Receptor Monoclonal Antibody)
Target (Total: 16)
  • Plexion/Plexion TS/Plexion SCT (Sodium Sulfacetamide/Sulfur)
  • Dynacin (Minocycline Hydrochloride)
  • Solodyn Extended Release Tablet (Minocycline HCl)
  • Ziana Gel (Clindamycin/Tretinoin)
Buyer

n/a
Target
  • Restylane (Hyaluronic Acid)
  • Perlane (Hyaluronic Acid)

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 17)
  • Micromet Inc. (MITI)
  • Infinity Pharmaceuticals Inc. (INFI)
  • Critical Therapeutics, Inc. (CRTX)
  • Option Care, Inc. (OPTN)
Target (Total: 4)
  • sanofi-aventis (ADR) (SNY)
  • Patheon, Inc. (PTI:CA)
  • Q-Med, Inc. (QMED)
  • Contract Pharmaceuticals Limited
Buyer (Total: 10)
  • AmerisourceBergen Corp. (ABC)
  • McKesson Corporation (MCK)
  • Cardinal Health, Inc. (CAH)
  • Abbott Laboratories (ABT)
Target (Total: 4)
  • McKesson Corporation (MCK)
  • Cardinal Health, Inc. (CAH)
  • BioMarin Pharmaceutical Inc. (BMRN)
  • Taro Pharmaceutical Industries Ltd. (TAROF)

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 2,359 391
Revenue Per Employee 976,913.8 978,208.3
Total Revenue 574.8 95.1
Total Expenses 342.4 86.2
Other Revenue 0.0 0.0
Cost of Revenue 115.5 10.5
SG&A Expense 147.1 62.3
Research & Development 79.5 8.0
Other Operating Expense 0.3 0.0
Operating Income 232.4 8.9
Unusual Income 0.0 0.0
LT Debt to Capital 44.29 45.94
Fwd P/E 64.37 26.78
Fwd P/Rev 9.51 3.83
Book Value 1,464.4 533.1
Curr Portion of LTD/Cap Lease 0.0 0.0

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals > Infectious Diseases > Viral

Target

Focused (): *Healthcare > Biopharmaceuticals > Dermatology

Business Description

Buyer

MedImmune, Inc. is a biotechnology company focusing its efforts on the therapeutic areas of infectious disease, cancer and inflammatory disease. The Company primarily develops monoclonal antibodies and vaccines. MedImmune markets three products: Synagis (palivizumab) and FluMist (Influenza Virus Vaccine Live, Intranasal) to help prevent two common respiratory infectious diseases, and Ethyol (amifostine) to help reduce adverse side effects of certain anti-cancer chemotherapies and radiotherapies. The Company is also developing a pipeline of product candidates for potential commercialization. MedImmune operates facilities in the United States and Europe to manufacture and distribute one or more components of each of its products. The Company has established clinical, research, development, manufacturing and commercialization collaborations with other companies and organizations. In December 2006, MedImmune sold all rights to the CytoGam product line and related assets to ZLB Behring AG.

Target

Medicis Pharmaceutical Corporation (Medicis) is an independent specialty pharmaceutical company focused primarily on helping patients attain a healthy and youthful appearance and self-image through the development and marketing in the United States of products for the treatment of dermatological, aesthetic and podiatric conditions. It also markets products in Canada for the treatment of dermatological and aesthetic conditions. It offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, skin and skin-structure infections, seborrheic dermatitis and cosmesis (improvement in the texture and appearance of skin). It offers 17 branded products, including OMNICEF (cefdinir), RESTYLANE (hyaluronic acid), SOLODYN (minocycline HCl, USP), TRIAZ (benzoyl peroxide), VANOS (fluocinonide) Cream 0.1%, and ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 76.35 89.15
Operating Margin % 11.19 -9.91
Quick Ratio 3.64 6.77
Current Ratio 3.98 7.53
Coverage Ratio 0.61 -0.61
Total Assets 3,033.5 1,084.0
Return on Equity % 11.04 4.12
Return on Assets % 5.33 2.03
Cash+ ST Inv. Per Share 4.3 8.99
Total Debt 1,164.1 453.1
Total Debt to Equity % 79.49 84.98
Total Debt to Tangible Equity % 91.37 148.43
Debt to Asset % 38.37 41.79

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
  
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
  
Medical Devices  
Plastic/Reconstructive Surgery
The Plastic/Reconstructive Surgery Subsector includes medical devices that treat and modify a patient's external appearance.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Dermatology
Acne  
Rosacea  
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat chronic inflammatory disorder of the face characterized by redness and pimple formation by inhibiting bacterial folic acid synthesis.

Target Products:

  • Plexion/Plexion TS/Plexion SCT (Sodium Sulfacetamide/Sulfur)
  
Vulgaris  
Antibacterial Agents  
Tetracyclines
Therapeutics that treat acne caused by bacterial infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.

Target Products:

  • Dynacin (Minocycline Hydrochloride)
  • Solodyn Extended Release Tablet (Minocycline HCl)
  
Antibacterial Agents/Retinoids
Therapeutics that treat acne by preventing bacterial growth and helping in cell differentiation.

Target Products:

  • Ziana Gel (Clindamycin/Tretinoin)
  
Keratolytic Agents
Therapeutics that soften, separate, and cause the shedding of skin.

Target Products:

  • Triaz (Benzoyl Peroxide)
  
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat bacterial infections of the skin by inhibiting a bacterial enzyme responsible for synthesis of folic acid.

Target Products:

  • Plexion/Plexion TS/Plexion SCT (Sodium Sulfacetamide/Sulfur)
  
Aging Disorders  
Wrinkles  
Acetylcholine Inhibitors
Therapeutics that treat wrinkling through prevention of muscle contractions that can result in the formation of facial lines.

Target Products:

  • Reloxin (Botulinum Toxin Type A)
  
Lesion/Scaling Disorders  
Dermatitis  
Atopic (Eczema)  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat atopic dermatoses by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Target Products:

  • Synalar (Fluocinolone Acetonide)
  
Seborrheic (Dandruff)  
Antifungal Agents  
Imidazoles
Therapeutics that treat and prevent skin diseases caused by fungi.

Target Products:

  • Loprox (Ciclopirox)
  
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat bacterial infections of the skin by inhibiting a bacterial enzyme responsible for synthesis of folic acid.

Target Products:

  • Plexion/Plexion TS/Plexion SCT (Sodium Sulfacetamide/Sulfur)
  
Dermatoses  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Target Products:

  • Lidex (Fluocinonide)
  • Vanos (Fluocinonide)
  
Pruritus  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Target Products:

  • Vanos (Fluocinonide)
  
Psoriasis  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Target Products:

  • Synalar (Fluocinolone Acetonide)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • MEDI-545 (Anti-Interferon Alpha Monoclonal Antibody)
  
Pigmentation Disorders  
Hyperpigmentation  
Enzymatic Oxidation Inhibitors
Therapeutics that treat disorders characterized by darkening of the skin by inhibiting metabolic processes of pigment producing skin cells.

Target Products:

  • Esoterica (Hydroquinone)
  
Endocrinology/Metabolism  
Intermediary Metabolism Disorders  
Urea Cycle Disorders  
Glutamine Acetylyzing Agents
Therapeutics that conjugate with glutamine to help excrete nitrogen waste.

Target Products:

  • Buphenyl (Sodium Phenylbutyrate)
  • Ammonul (Sodium Phenylacetate, Sodium Benzoate)
  
Immunology
Autoimmune Disorders  
Psoriasis  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat a chronic autoimmune disease characterized by softening, separating, causing the shedding of the horny layer of the skin with a steroidal compound.

Target Products:

  • Synalar (Fluocinolone Acetonide)
  • Vanos (Fluocinonide)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • MEDI-545 (Anti-Interferon Alpha Monoclonal Antibody)
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • MDX-1103 (Human Antibodies)
  • MEDI-546 (Anti-Type 1 Interferon Receptor Monoclonal Antibody)
  • Anti-Chitinase MAb
  • Anti-CD19/Anti-CD20/Anti-CD22 Monoclonal Antibodies
  • Anti-HMGB1 Monoclonal Antibody
  • Anti-ICOS MAbs
  
Infectious Diseases
Bacterial  
Antibacterial Agents  
Broad Spectrum  
Antibiotics  
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.

Target Products:

  • Omnicef (Cefdinir)
  
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.

Target Products:

  • Dynacin (Minocycline Hydrochloride)
  
Mycological (Fungal)
Antifungal Agents
Narrow Spectrum
Dermatology  
Tinea Corporis (Ringworm)  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Target Products:

  • Loprox (Ciclopirox)
  
Tinea Cruris (Jock Itch)  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the groin and perineum by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Target Products:

  • Loprox (Ciclopirox)
  
Tinea Pedis  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of the feet by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Target Products:

  • Loprox (Ciclopirox)
  
Tinea Versicolor  
Azoles  
Imidazoles
Therapeutics that treat fungal infections of skin exposed to the sun characterized by patches of depigmentation by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Target Products:

  • Loprox (Ciclopirox)
  
Respiratory System  
Pneumocystis Carinii Pneumonia (PCP)  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat infections of the lungs of immunocompromised patients caused by Pneumocystis carinii by blocking the action of dihydrofolate reductase.

Buyer Products:

  • Neutrexin (Trimetrexate Glucuronate)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Buyer Products:

  • RSV/Anti-Human Metapneumovirus (hMPV)/Parainfluenzavirus (PIV) Vaccine
  • Anti-Human Metapneumovirus Monoclonal Antibody
  • RSV Vaccine
  • Epstein-Barr Virus (EBV) Vaccine
  • Streptococcus pneumoniae Vaccine
  • Intranasal H5N1 Influenza Vaccine
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.

Buyer Products:

  • EphA2 Antagonists
  • Streptococcus pneumoniae Vaccine
  • Anti-Candida HP Monoclonal Antibody
  • Anti-Staphylococcal HP Monoclonal Antibody
  • Anti-RSV Drug
  • Third Generation Respiratory Syncitial Virus (RSV) Monoclonal Antibody
  • Anti-HMGB1 Monoclonal Antibody
  
Viral  
RNA Viruses  
Paramyxovirus  
Respiratory Syncytial Virus (RSV)  
Immunoglobulins
Therapeutics that treat viral infections in the respiratory tracts of infants with a variety of specific protein that neutralizes the virus.

Buyer Products:

  • RespiGam (Respiratory Syncytial Virus Immune Globulin Intravenous)
  
Monoclonal Antibodies
Therapeutics that treat viral infections in the respiratory tracts of infants with a neutralizing protein that targets a specific site on the virus.

Buyer Products:

  • Numax (Anti-RSV MAb)
  • Synagis (Palivizumab)
  • Liquid Synagis (Palivizumab)
  
Vaccines  
Viral  
Single Target  
Influenza (Flu)
Therapeutics that prevent or treat viral infections of the respiratory tract by producing or artificially increasing immunity to the Influenza virus.

Buyer Products:

  • FluMist (Influenza Virus Vaccine Live, Intranasal)
  • FluMist Refrigerated Formualtion (Influenza Vaccine Live, Intranasal)
  
Musculoskeletal System  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Anti-HMGB1 Monoclonal Antibody
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  
Oncology  
Head/Neck Cancer  
Palliative Agents  
Thiophosphate Cytoprotective Agents
Therapeutics that treat nephropathy associated with repeated cisplatin treament for head and neck cancers.

Buyer Products:

  • Ethyol (Amifostine)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • MT103/MEDI-538 (T-Cell Engager)
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • Intravenous IPI-504 (Hsp90 inhibitor)
  • Ethyol (Amifostine)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.

Buyer Products:

  • Anti-EphB4/Anti-EphrinB2 Antibodies
  • cMET Receptor Antagonists
  • EphA4 Agonists
  • Anti-CD19/Anti-CD20/Anti-CD22 Monoclonal Antibodies
  • Anti-ALK Monoclonal Antibody
  • EphA2 Antagonists
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • Hedgehog Antagonist
  • Anti-Chitinase MAb
  
Respiratory System/Thoracic  
Lung Cancer  
Non Small Cell Lung Cancer (NSCLC)  
Palliative Agents  
Thiophosphate Cytoprotective Agents
Therapeutics that treat nephropathy associated with repeated cisplatin treatment for cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma

Buyer Products:

  • Ethyol (Amifostine)
  
Urology  
Ovarian Cancer  
Palliative Agents  
Thiophosphate Cytoprotective Agents
Therapeutics that treat nephropathy associated with repeated cisplatin treatment for cancers of the ovaries.

Buyer Products:

  • Ethyol (Amifostine)
  
Respiratory System  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • BIW-8405 (IL-5 Monoclonal Antibody)
  • MEDI-528 (IL-9 Monoclonal Antibody)
  
Medical Devices  
Plastic/Reconstructive Surgery  
Treatment  
Wrinkle Removal  
Hyaluronic Acid  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Johnson & Johnson n/a 181,816.951 17.62 15.46 3.28 2.98 15.54
sanofi-aventis (ADR) n/a 113,703.100 20.78 11.45 2.82 2.92 n/a
Bristol Myers Squibb Co. n/a 60,537.680 38.78 21.16 3.42 3.01 16.56
Buyer
  Pfizer Inc. n/a 185,773.425 9.98 12.27 3.78 3.88 6.62
Johnson & Johnson n/a 181,816.951 17.62 15.46 3.28 2.98 15.54
Target
  Johnson & Johnson n/a 181,816.951 17.62 15.46 3.28 2.98 15.54
sanofi-aventis (ADR) n/a 113,703.100 20.78 11.45 2.82 2.92 n/a
Bristol Myers Squibb Co. n/a 60,537.680 38.78 21.16 3.42 3.01 16.56
Allergan, Inc. n/a 18,031.493 49.92 27.25 5.42 4.91 293.67
Shire plc (ADR) n/a 13,353.002 40.49 35.28 6.98 5.87 6.87
Cytyc Corporation n/a 4,862.681 82.46 31.18 7.64 6.39 n/a
Warner Chilcott Ltd. n/a 4,427.505 n/a 18.57 5.49 5.15 n/a
Biovail Corporation (USA) n/a 4,066.947 17.16 13.56 3.72 4.70 7.28
Valeant Pharmaceuticals International n/a 1,652.467 n/a 23.41 1.79 1.81 n/a
Sciele Pharma Inc. n/a 878.377 17.88 14.49 2.84 2.30 8.36
XOMA Limited n/a 447.748 n/a -11.10 12.39 8.12 n/a
Obagi Medical Products, Inc. n/a 395.924 52.46 25.17 4.72 3.78 38.58
Bradley Pharmaceuticals, Inc. n/a 348.768 29.09 29.75 2.36 2.14 176.50
CollaGenex Pharmaceutical, Inc n/a 261.768 n/a -14.30 7.09 4.18 4.56
Taro Pharmaceutical Industries Ltd. n/a 215.087 37.89 22.09 0.72 0.70 0.91
Barrier Therapeutics, Inc. n/a 181.206 n/a -3.67 20.16 6.92 4.91
Artes Medical, Inc. n/a 138.447 n/a -5.86 96.04 9.66 3.66
DFB Pharmaceuticals, Inc. n/a n/a n/a n/a n/a n/a n/a
Nestle S.A. n/a n/a n/a 16.98 n/a n/a n/a
Groupe L'Oreal n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Micromet Inc. 19.00% 82.856 n/a -2.53 3.16 5.32 26.73
Infinity Pharmaceuticals Inc. 18.00% 208.108 n/a -9.56 8.71 9.09 3.43
Critical Therapeutics, Inc. 10.00% 104.389 n/a -3.05 7.30 4.67 2.25
Option Care, Inc. 9.50% 535.901 22.65 20.26 0.75 0.66 16.40
Seattle Genetics, Inc. 9.30% 564.933 n/a -14.03 46.30 29.38 6.92
PDL BioPharma Inc. 8.00% 2,877.777 n/a 73.88 6.67 5.94 24.10
Abbott Laboratories n/a 84,288.496 54.40 19.28 3.73 3.72 n/a
Baxter International Inc. n/a 37,709.816 24.84 21.71 3.54 3.43 8.34
Cardinal Health, Inc. n/a 26,906.163 19.93 20.66 0.31 0.31 7.77
Becton, Dickinson and Co. n/a 18,677.709 24.39 20.13 3.11 2.96 5.58
Medarex, Inc. n/a 1,924.479 n/a -62.54 40.86 41.21 3.45
Human Genome Sciences n/a 1,365.526 n/a -5.98 48.47 26.89 7.89
Applix, Inc. n/a 255.585 25.58 40.35 4.48 3.79 12.00
Dyax Corp. n/a 223.889 n/a -3.64 17.58 13.74 10.98
Cerus Corporation n/a 196.206 n/a -5.07 5.90 11.01 2.07
SM&A n/a 131.566 33.71 17.50 1.69 1.44 4.31
Avalon Pharmaceuticals, Inc. n/a 65.589 n/a -2.92 22.49 19.33 2.88
Target
  sanofi-aventis (ADR) n/a 113,703.100 20.78 11.45 2.82 2.92 n/a
Patheon, Inc. n/a 382.060 n/a n/a 0.53 n/a 1.93
Q-Med, Inc. n/a 51.266 n/a -5.81 3.93 1.17 4.09
Contract Pharmaceuticals Limited n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  McKesson Corporation 18.00% 18,039.456 19.76 18.84 0.19 0.18 5.76
Cardinal Health, Inc. 15.00% 26,906.163 19.93 20.66 0.31 0.31 7.77
Buyer
  AmerisourceBergen Corp. 29.00% 9,647.715 19.56 19.88 0.15 0.15 6.93
McKesson Corporation 18.00% 18,039.456 19.76 18.84 0.19 0.18 5.76
Cardinal Health, Inc. 15.00% 26,906.163 19.93 20.66 0.31 0.31 7.77
Abbott Laboratories 12.00% 84,288.496 54.40 19.28 3.73 3.72 n/a
GlaxoSmithKline plc (ADR) n/a 150,489.154 14.15 13.27 3.32 3.23 14.40
Merck & Co., Inc. n/a 109,945.758 23.81 17.14 4.78 4.69 6.80
Medco Health Solutions Inc. n/a 22,523.128 26.18 23.05 0.52 0.49 n/a
Option Care, Inc. n/a 535.901 22.65 20.26 0.75 0.66 16.40
GTC Biotherapeutics, Inc. n/a 90.373 n/a -2.74 9.66 12.98 3.21
Government - United States n/a n/a n/a n/a n/a n/a n/a
Target
  McKesson Corporation 56.80% 18,039.456 19.76 18.84 0.19 0.18 5.76
Cardinal Health, Inc. 19.30% 26,906.163 19.93 20.66 0.31 0.31 7.77
BioMarin Pharmaceutical Inc. n/a 1,703.357 n/a -79.18 18.27 14.16 12.82
Taro Pharmaceutical Industries Ltd. n/a 215.087 37.89 22.09 0.72 0.70 0.91

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  sanofi-aventis (ADR) n/a 113,703.100 20.78 11.45 2.82 2.92 n/a
Abbott Laboratories n/a 84,288.496 54.40 19.28 3.73 3.72 n/a
Cardinal Health, Inc. n/a 26,906.163 19.93 20.66 0.31 0.31 7.77
Buyer
  GlaxoSmithKline plc (ADR) n/a 150,489.154 14.15 13.27 3.32 3.23 14.40
Novartis AG (ADR) n/a 130,940.797 23.99 16.65 3.43 3.42 3.23
sanofi-aventis (ADR) n/a 113,703.100 20.78 11.45 2.82 2.92 n/a
Merck & Co., Inc. n/a 109,945.758 23.81 17.14 4.78 4.69 6.80
Abbott Laboratories n/a 84,288.496 54.40 19.28 3.73 3.72 n/a
Schering-Plough Corporation n/a 46,156.165 36.96 24.25 4.19 3.89 5.98
Baxter International Inc. n/a 37,709.816 24.84 21.71 3.54 3.43 8.34
Teva Pharmaceutical Industries Ltd (ADR) n/a 31,840.000 16.79 17.90 3.61 3.47 23.48
Cardinal Health, Inc. n/a 26,906.163 19.93 20.66 0.31 0.31 7.77
Target
  sanofi-aventis (ADR) n/a 113,703.100 20.78 11.45 2.82 2.92 n/a
Abbott Laboratories n/a 84,288.496 54.40 19.28 3.73 3.72 n/a
Cardinal Health, Inc. n/a 26,906.163 19.93 20.66 0.31 0.31 7.77
McKesson Corporation n/a 18,039.456 19.76 18.84 0.19 0.18 5.76
BioMarin Pharmaceutical Inc. n/a 1,703.357 n/a -79.18 18.27 14.16 12.82
Patheon, Inc. n/a 382.060 n/a n/a 0.53 n/a 1.93
Taro Pharmaceutical Industries Ltd. n/a 215.087 37.89 22.09 0.72 0.70 0.91
Q-Med, Inc. n/a 51.266 n/a -5.81 3.93 1.17 4.09
Ipsen S.A. n/a n/a n/a n/a n/a n/a n/a
AAIPharma Inc. n/a n/a n/a n/a n/a n/a n/a
Contract Pharmaceuticals Limited n/a n/a n/a n/a n/a n/a n/a
Dow Pharmaceutical Sciences, Inc. n/a n/a n/a n/a n/a n/a n/a
Astellas Pharma Inc. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 1,353.6 369.2 1,722.8
Other Revenue 0.0 0.0 0.0
Total Revenue 1,353.6 369.2 1,722.8
Cost of Revenue 320.1 40.1 360.2
SG&A Expense 476.4 217.9 694.3
Depreciation & Amortization 0.0 22.6 22.6
Research & Development 440.5 72.6 513.1
Interest Expense 0.0 0.0 0.0
Other Operating Expense 13.6 0.0 13.6
Unusual Expense (Income) -48.5 52.6 4.1
Total Expenses 1,202.1 405.8 1,607.9
Operating Income 151.5 -36.6 114.9
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 92.9 22.1 115.0
Other, Net 0.0 0.0 0.0
Income Before Taxes 244.4 -14.4 230.0
Income Taxes 82.7 -36.4 46.3
Income After Taxes 161.7 22.0 183.7
Net Income - Excl. Xord. Items 161.7 22.0 183.7
Net Income - Incl. Xord. Items 161.7 22.0 183.7
Income Avail. to Common 161.7 22.0 183.7
Share Items
Basic Avg. Shares Outstanding 237.9 55.6 293.5
Basic EPS - Excl. Xord. Items 0.68 0.40 0.63
Basic EPS - Incl. Xord. Items 0.68 0.40 0.63
Full Dilution Adjustment 0.0 1.7 1.7
Fully Diluted Shares Outstanding 241.4 71.7 313.1
F.D. EPS - Excl. Xord. Items 0.67 0.31 0.59
F.D. EPS - Incl. Xord. Items 0.67 0.31 0.59
Dividends Per Common Share 0.00 0.12 0.12
Balance Sheet
Assets
Cash and Equivalents 463.3 83.9 547.2
ST Investments 574.2 560.6 1,134.8
Accounts Receivable 280.6 18.0 298.6
Inventory 87.6 30.8 118.4
Other Current Assets 35.3 43.7 79.0
Current Assets 1,441.0 737.0 2,178.0
Accum D&A 0.0 0.0 0.0
PPE, Net 502.8 7.5 510.3
Goodwill & Intangibles 190.4 227.9 418.3
Long Term Investments 566.4 0.0 566.4
Other Assets 0.0 0.0 0.0
Other LT Assets 332.9 111.7 444.6
Total Assets 3,033.5 1,084.0 4,117.5
Liabilities
Accounts Payable 45.1 51.4 96.5
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 185.3 0.0 185.3
ST Debt 0.0 0.0 0.0
Other (Current) Liabilities 131.8 46.5 178.3
Current Liab. 362.2 97.9 460.1
LT Debt 1,164.1 453.1 1,617.2
Total LT Debt 1,164.1 453.1 1,617.2
Other LT Liab. 42.8 0.0 42.8
Total Liabilities 1,569.1 550.9 2,120.0
Shareholders Equity
Common Stock 2.6 1.0 3.6
Additional Paid in Capital 2,713.7 615.2 3,328.9
Retained Earnings -705.7 259.2 -446.5
Treasure Stock -540.5 -342.9 -883.4
Other Equity -5.7 0.7 -5.0
Total Equity 1,464.4 533.1 1,997.5
Total Liab. & Equity 3,033.5 1,084.0 4,117.5
Shares Outstanding 237.7 55.8 293.5
Cash Flow
Operating Cash Flow
CF Net Income 161.7 22.0 183.7
CF Depreciation 117.8 22.6 140.4
CF Deferred Taxes -11.5 -57.1 -68.6
Other Non-Cash Items -26.8 91.2 64.4
Change in Working Capital -346.0 17.5 -328.5
Total Cash From Operating Activities -104.8 96.3 -8.5
Investing Cash Flow (not calculated)
Capital Expenditures -145.6 -8.0 -153.6
Other Investing Cash Flows 417.7 -274.3 143.4
Total Cash From Investing Activities 272.1 -282.2 -10.1
Financing Cash Flow (not calculated)
Dividends Paid 0.0 -6.6 -6.6
Purchase Or Sale of Stock -179.8 27.7 -152.1
Purchase and Retirement of Debt 638.5 0.0 638.5
Other Financing Cash Flow -310.6 3.0 -307.6
Total Cash From Financing Activities 148.1 24.1 172.2
Exchange Rate Effects -0.1 -0.1 -0.2
Net Change in Cash 315.3 -161.9 153.4
Cash Taxes Paid 2.0 35.7 37.7
Cash Interest Paid 3.8 0.0 3.8